Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
ID: 360627Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360627
Timeline
    Description

    The National Institutes of Health (NIH) is seeking a qualified entity to continue the Physiology of the Weight Reduced State (POWERS) Study through a cooperative agreement. This initiative aims to further investigate the physiological processes that contribute to individual differences in weight regain after weight loss, allowing for the completion of the clinical trial and subsequent data analysis. The POWERS study is critical for understanding obesity and developing effective weight management strategies. Interested applicants should note that the estimated project start date is April 1, 2027, with a single award anticipated, and they can contact Dr. Mary Evans at NIDDK_Obesity@nih.gov or by phone at 301-594-4578 for further information.

    Point(s) of Contact
    Mary Evans, PhD
    (301) 594-4578
    NIDDK_Obesity@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a Cooperative Agreement to establish a Research Coordinating Center (RCC) focused on optimal treatment strategies for the use of anti-obesity medications (AOMs) in children and adolescents. The RCC will coordinate a consortium of clinical centers to evaluate various AOM treatment strategies, including the timing of AOM initiation, weight loss rates, medication classes, dosages, and the integration of lifestyle therapies to support healthy development and minimize long-term reliance on AOMs. This initiative is critical for addressing obesity in youth and ensuring effective treatment protocols, with one award expected to be made. Interested applicants can reach out to Dr. Stavroula K. Osganian at (301) 827-6939 or via email at voula.osganian@nih.gov for further details. The estimated project start date is July 1, 2027, with applications due by December 1, 2026.
    Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a cooperative agreement aimed at developing optimal treatment strategies for the use of anti-obesity medications (AOMs) in children and adolescents. This initiative seeks clinical centers to join a consortium focused on testing AOM treatment strategies that maximize benefits while minimizing risks, emphasizing healthy growth, nutritional intake, and mental well-being. The project is critical in addressing obesity in youth, with a focus on determining the best developmental stages for AOM initiation and evaluating predictors of treatment response. Interested applicants can reach out to Dr. Stavroula K. Osganian at (301) 827-6939 or via email at voula.osganian@nih.gov. The estimated award date is July 1, 2027, with applications due by December 1, 2026, and a total of three awards expected.
    Nutrition Obesity Research Centers (NORCs)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Nutrition Obesity Research Centers (NORCs) program, which aims to establish core centers that contribute to an integrated program of nutrition and obesity research. This funding opportunity supports three primary research-related activities: Research Core services, a Pilot and Feasibility program, and an Enrichment program, all designed to enhance the efficiency and multidisciplinary nature of research in this critical health area. With an estimated total program funding of $3.6 million and the expectation of awarding three grants, interested applicants can reach out to Dr. Mary Evans at evansmary@niddk.nih.gov or call 301-594-4578 for further information. The application process is open until October 1, 2026, with awards anticipated to be made by June 1, 2027.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01-Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk," aimed at supporting research that evaluates policies influencing obesity-related behaviors and chronic disease risk. Applicants must demonstrate that their proposed evaluations represent unique research opportunities that necessitate prompt initiation, particularly focusing on policies affecting diet, physical activity, and weight outcomes in populations vulnerable to health disparities. This initiative reflects NIH's commitment to addressing critical public health issues through scientific evaluation and community-focused approaches, with a maximum project duration of five years and no specific budget limits. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 11, 2028.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source: National Longitudinal Study of Adolescent to Adult (Add) Health Wave VII (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the renewal of the National Longitudinal Study of Adolescent to Adult Health (Add Health) for a new five-year study period. This initiative aims to continue core study aspects, including the collection, development, and dissemination of high-quality population-representative data to help the research community understand life course factors influencing inequities in aging-related outcomes. The funding will be provided through a cooperative agreement, with no cost-sharing or matching requirements, and is categorized under health-related activities. Interested applicants, particularly those with expertise in aging research, are encouraged to start forming collaborations in anticipation of the application process, which is expected to open following the estimated synopsis post date of August 15, 2025, and close by October 15, 2025. For further inquiries, potential applicants can contact Dr. Amelia Karraker at amelia.karraker@mail.nih.gov or by phone at 301-496-3131.
    The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development," aimed at enhancing the understanding of complex metabolic diseases, particularly Type 2 Diabetes (T2D). This initiative seeks to renew the AMP CMD UM1 program for an additional five years, focusing on the aggregation and collation of genetic data related to T2D and its complications, thereby facilitating research and therapeutic advancements in the field. The program is critical for leveraging human genetics to uncover disease mechanisms and potential biomarkers, with an estimated total funding of $3 million and the expectation of one award. Interested applicants, including small businesses and various organizations, should contact Dr. Norann Zaghloul at Norann.zaghloul@nih.gov or call 301-435-6677 for further details, with proposals due by March 1, 2026, and awards anticipated by December 1, 2026.